Tyme Technologies, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-10-18: Form 8-K; Period of report 2019-10-18; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2019-10-17: Form 8-K; Period of report 2019-10-02; Description 1.02 Termination of a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; Details 1.02.
- 2019-09-25: Form 8-K; Period of report 2019-09-25; Description 8.01 Other Events; Details 8.01.
- 2019-08-27: Form 8-K; Period of report 2019-08-22; Description 5.07 Submission of Matters to a Vote of Security Holders.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-10-18 | 8-K | 2019-10-18 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 The opinion of Drinker Biddle & Reath LLP regarding the legality of the issuance of the Shares is attached as Exhibit 5.1 hereto and is incorporated by reference into the Registration Statement. | d814527d8k.htm |
| 2019-10-17 | 8-K | 2019-10-02 | 1.02 Termination of a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition | 1.02 On October 2, 2019, Tyme sent notice to Canaccord Genuity LLC (“Canaccord”) that it was terminating the equity distribution agreement, dated November 2, 2017, by and between the parties (the “Equity Distribution Agreement”). 2.02 On October 17, 2019, Tyme released financial information for the second quarter ended September 30, 2019. | d811700d8k.htm |
| 2019-09-25 | 8-K | 2019-09-25 | 8.01 Other Events | 8.01 On September 25, 2019, Tyme announced the start of its pivotal study to evaluate the clinical benefits of its lead cancer metabolism-based therapy (CMBT™) candidate, oral SM-88 (racemetyrosine), for third-line treatment of patients with metastatic pancreatic cancer. | d778208d8k.htm |
| 2019-08-27 | 8-K | 2019-08-22 | 5.07 Submission of Matters to a Vote of Security Holders | d789726d8k.htm | |
| 2019-07-09 | 8-K | 2019-07-09 | 7.01 Regulation FD Disclosure | 7.01 As previously disclosed, Tyme’s management will be hosting a conference call today, July 9, 2019, to discuss the data presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain on Wednesday, July 4, 2019. | d772766d8k.htm |
| 2019-07-05 | 8-K | 2019-07-05 | 7.01 Regulation FD Disclosure | 7.01 On July 5, 2019, Tyme issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d770087d8k.htm |
| 2019-05-29 | 8-K | 2019-05-29 | 2.02 Results of Operations and Financial Condition | 2.02 On May 29, 2019, Tyme released financial information for the year and fourth quarter ended March 31, 2019. | d731508d8k.htm |
| 2019-05-20 | 8-K | 2019-05-20 | 7.01 Regulation FD Disclosure | 7.01 On May 20, 2019, Tyme issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d751606d8k.htm |
| 2019-04-02 | 8-K | 2019-03-28 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On March 28, 2019, Tyme entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC as the representative of the underwriters named therein (the “Underwriter”), related to the registered offering (the “Offering”) of 8,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and warrants to purchase up to 8,000,000 shares of Common Stock (the “Warrants” and, together with the Shares, the “Securities”) with an exercise price of $2.00 per share at a combined purchase price of $1.50 per share of Common Stock and accompanying Warrant. 8.01 The legal opinion and consent of Drinker Biddle & Reath LLP relating to the validity of the shares is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d704211d8k.htm |
| 2019-03-18 | 8-K | 2019-03-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On March 18, 2019, the Company announced the departure of Michael Demurjian as Executive Vice President, Chief Operating Officer and director of the Company. 8.01 On March 15, 2019, the Board approved an extension of the exercise period for certain warrant agreements representing warrants to purchase up to 3,483,521 shares of common stock. | d722912d8k.htm |
| 2019-02-25 | 8-K | 2019-02-25 | 7.01 Regulation FD Disclosure | 7.01 On February 25, 2019, Tyme issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d712079d8k.htm |
| 2019-02-14 | 8-K | 2019-02-14 | 8.01 Other Events | 8.01 On February 14, 2019, Tyme issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d706314d8k.htm |
| 2019-01-18 | 8-K | 2019-01-18 | 7.01 Regulation FD Disclosure | d693906d8k.htm | |
| 2019-01-18 | 8-K | 2019-01-18 | 8.01 Other Events | 8.01 On January 18, 2019, Tyme issued a press release relating to the SM-88 preliminary Phase II pancreatic cancer data from its ongoing Phase II Pancreatic Cancer Trial, which data analysis will be presented today at ASCO GI. | d678702d8k.htm |
| 2019-01-15 | 8-K | 2019-01-15 | 8.01 Other Events | 8.01 On January 15, 2019, Tyme issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d611086d8k.htm |
| 2019-01-03 | 8-K | 2018-12-31 | 8.01 Other Events | 8.01 On December 31, 2018, Tyme filed a registration statement with the Securities and Exchange Commission to register the resale of shares of our common stock, including shares issuable upon exercise of warrants, currently held by our security holders named therein. | d676278d8k.htm |